1. Home
  2. ENTX vs LICN Comparison

ENTX vs LICN Comparison

Compare ENTX & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • LICN
  • Stock Information
  • Founded
  • ENTX 2010
  • LICN 2004
  • Country
  • ENTX Israel
  • LICN China
  • Employees
  • ENTX N/A
  • LICN N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • LICN
  • Sector
  • ENTX Health Care
  • LICN
  • Exchange
  • ENTX Nasdaq
  • LICN Nasdaq
  • Market Cap
  • ENTX 104.0M
  • LICN 3.1M
  • IPO Year
  • ENTX 2018
  • LICN 2023
  • Fundamental
  • Price
  • ENTX $1.80
  • LICN $4.15
  • Analyst Decision
  • ENTX Strong Buy
  • LICN
  • Analyst Count
  • ENTX 1
  • LICN 0
  • Target Price
  • ENTX $10.00
  • LICN N/A
  • AVG Volume (30 Days)
  • ENTX 37.8K
  • LICN 69.9K
  • Earning Date
  • ENTX 08-08-2025
  • LICN 01-01-0001
  • Dividend Yield
  • ENTX N/A
  • LICN N/A
  • EPS Growth
  • ENTX N/A
  • LICN N/A
  • EPS
  • ENTX N/A
  • LICN N/A
  • Revenue
  • ENTX $223,000.00
  • LICN $41,477,000.00
  • Revenue This Year
  • ENTX N/A
  • LICN N/A
  • Revenue Next Year
  • ENTX N/A
  • LICN N/A
  • P/E Ratio
  • ENTX N/A
  • LICN N/A
  • Revenue Growth
  • ENTX N/A
  • LICN 4.32
  • 52 Week Low
  • ENTX $1.41
  • LICN $2.60
  • 52 Week High
  • ENTX $2.79
  • LICN $488.00
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 38.86
  • LICN 47.92
  • Support Level
  • ENTX $1.75
  • LICN $4.02
  • Resistance Level
  • ENTX $1.99
  • LICN $4.41
  • Average True Range (ATR)
  • ENTX 0.11
  • LICN 0.26
  • MACD
  • ENTX -0.02
  • LICN 0.02
  • Stochastic Oscillator
  • ENTX 14.71
  • LICN 70.72

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: